



Effective management of pulmonary infection due to *Pseudomonas aeruginosa*

TOBI® Podhaler® (Tobramycin 28mg inhalation powder) is indicated for the suppressive therapy of chronic pulmonary infection due to *Pseudomonas aeruginosa* in adults and children aged 6 years and older with cystic fibrosis.

Prescribing information

Pseudomonas aeruginosa (Pa) is one of the most common bacterial pathogens found in cystic fibrosis (CF) patients. In 2021, 28% of CF patients had a positive culture for Pa.¹

Viatrix is hosting a number of workshops focusing on 'Effective management of chronic pulmonary infection due to *Pseudomonas aeruginosa*'. The workshops will be led by Thomas Tobin, Highly Specialised Physiotherapist at the Royal Brompton Hospital

We are delighted to invite you to attend one of the following workshops:

**Tuesday 14th March 2023
18:30–21:00**

**Thursday 27th April 2023
18:30–21:00**

**Thursday 18th May 2023
18:30–21:00**

These workshops are designed to be interactive. Where possible, we do encourage you to enable your webcam and microphone to participate in the sessions.

The new normal in CF

The CF landscape has changed dramatically over the last few years. The usage and perceptions surrounding the roles of antibiotics within CF have been changing.²

Many symptoms of CF are positively changed following treatment with CFTR modulator therapy.³

Do you have patients that have stopped their treatment or are less compliant with inhaled antibiotics following commencement of CFTR therapy? With an improved quality of life, do you find that your patients want to spend less time taking their medication and have more time to live their lives?

It is important to note that studies have shown that between 36% and 45% of patients treated with CFTR therapy remain positive for *Pseudomonas aeruginosa* following 5 years of treatment.^{4,5}

Do you find compliance is low for patients taking inhaled antibiotics? What techniques have you used to try and improve compliance?

An increase in colonisation of Pa may lead to a lower FEV₁, hospitalisation and mortality in patients with CF.^{6,7}

Chronic Pa infection in the lungs may cause chronic coughing, wheezing, inflammation and fibrosis and cysts within the lungs.⁸

BOOK YOUR PLACE HERE

During these workshops, we will explore the need to robustly manage chronic Pa infection as well as techniques to help improve patient compliance with inhaled antibiotics.

This is a promotional workshop, initiated, funded and reviewed by Viatrix. Brand names will be mentioned.

Viatrix has created a workbook that complements the workshop sessions.

More information can be found on our registration page with how you can request the workbook.

1. Annual Data Report 2021. Cystic Fibrosis Foundation Patient Registry website. www.cff.org/sites/default/files/2021-11/Patient-Registry-Annual-Data-Report.pdf. Accessed January 2023 2. Fiel SB, Roesch EA. Expert Rev Respir Med 2022;1–7 3. Keown K, et al. Int J Mol Sci 2020;21(17):6379; 4. Volkova N, et al. J Cyst Fibros 2020;19(1):68–79; 5. Frost FJ, et al. Ann Am Thorac Soc 2019;16(11):1375–1382 6. Emerson et al. 2002 7. Jarad et al 2005 8. Health conditions: cystic fibrosis. Genetics Home Reference website. <https://vsearch.nlm.nih.gov/vivisimo/cgi-bin/query-meta?v%3Aproject=medlineplus&v%3Asources=medlineplus-bundle&query=cystic+fibrosis>. Accessed January 2023

This workshop will explore the following points:



An overview of Pa and its impact on CF patients



The impact of CFTR therapy on Pa management



An update and review of the latest management guidance



Adapting treatment to fit into the "new normal"



The benefits of TOBI® Podhaler®



Meet the Speaker

THOMAS TOBIN

Tom is a highly specialised physiotherapist, working at the adult cystic fibrosis centre at the Royal Brompton Hospital in London, United Kingdom. Tom graduated from the University of the West of England with a first class honours degree in Physiotherapy in 2012. After completing his junior and senior rotations, he moved to the Royal Brompton Hospital to focus on the physiotherapy management of respiratory diseases in 2014. Tom has now specialised in the field of adult cystic fibrosis, with a specialist interest in non-invasive ventilation and end of life care. Tom is enrolled on an MSc in Advance Clinical Practice at Kings College and is passionate about developing the ACP role within Adult Cystic Fibrosis services.

BOOK YOUR PLACE HERE

This is a promotional workshop, initiated, funded and reviewed by Viatris. Brand names will be mentioned.

Prescribing information

Reporting of adverse reactions:

Please continue to report suspected adverse drug reactions and device failures with any medicine or vaccine to the MHRA through the Yellow Card Scheme.

It is easiest and quickest to report adverse drug reactions and device failures online via the Yellow Card website:

<https://yellowcard.mhra.gov.uk/> or search for MHRA Yellow Card in the Google Play or Apple App Store.

Alternatively, you can report via some clinical IT systems (EMIS/SystmOne/Vision/MiDatabank) or by calling the Commission on Human Medicines (CHM) free phone line: 0800-731-6789.

*Adverse reactions/events and device failures should also be reported to MAH at e-mail address: **pv.uk@viatris.com**.*